FDA expands approval of flu treatment to post-exposure prevention
The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who have been exposed to someone with flu.
“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the FDA’s Division of Antiviral Products.
Related News Articles
Headline
The Central Nevada Health District yesterday announced the state's first case of H5N1 bird flu, a dairy farm worker who was exposed to infected cattle. The…
Headline
At least 24 million people have had seasonal flu this season, according to estimates from the Centers for Disease Control and Prevention. Nearly 49,000…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Centers for Disease Control and Prevention today released an advisory recommending clinicians expedite subtyping of type A influenza samples from…
Headline
The Louisiana Department of Health yesterday announced that a patient hospitalized last month for H5N1 bird flu has died, becoming the first U.S. death from…
Headline
AHA’s latest social media toolkit for encouraging vaccination against the flu and COVID-19 focuses on vaccination during peak respiratory virus season. The…